<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) corresponds to the third most prevalent type of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Its origins can either be <z:hpo ids='HP_0003745'>sporadic</z:hpo> or inherited, being <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> the most common form of hereditary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The activation of BRAF oncogene, inactivation of mismatch repair genes by methylation of CpG islands, and microsatellite instability (MSI) have been reported to be involved in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development </plain></SENT>
<SENT sid="3" pm="."><plain>The goal of the study was to characterize <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> using clinical and molecular criteria through association and cluster analysis </plain></SENT>
<SENT sid="4" pm="."><plain>Amsterdam II and Bethesda guidelines and molecular variables were analyzed in 77 patients from Brazil </plain></SENT>
<SENT sid="5" pm="."><plain>The replication error (RER) status, based in microsatellite instability, showed association with metachronous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, MLH1 gene methylation and inverse association with left-sided and synchronous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The PMS2 gene was considered the best predictor for differentiating levels of methylation and the <z:chebi fb="0" ids="29075">mononucleotide</z:chebi> were considered the best markers to evaluate RER status </plain></SENT>
<SENT sid="7" pm="."><plain>The cluster 1 was characterized of individuals over 60 years of age, female, right-sided <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, high microsatellite instability, and metachronous or synchronous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The individuals in cluster 2 were younger than 45 years of age, male and showed left sided or rectum <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and microsatellite stability </plain></SENT>
<SENT sid="9" pm="."><plain>Even though it was not observed a significant association, a higher number of individuals with family history of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> without promoter methylation were found in cluster 2 </plain></SENT>
<SENT sid="10" pm="."><plain>The V600E mutation did not show association with clinical or molecular characteristics </plain></SENT>
<SENT sid="11" pm="."><plain>Evaluation of MSI and methylation of MLH1 and PMS2 genes should be considered in order to assist with clinical diagnosis </plain></SENT>
</text></document>